8-K: Phio Pharmaceuticals Reports Positive Clinical Trial Results and First Quarter 2025 Financials

Phio Pharmaceuticals announces encouraging Phase 1b clinical trial results for PH-762 and reports its financial results for the first quarter of 2025.

Summary

• Phio Pharmaceuticals reported its financial results for the quarter ended March 31, 2025, and provided a business update.
• The company's ongoing Phase 1b dose escalation clinical trial is evaluating the safety and tolerability of PH-762 in patients with cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma.
• Of the 9 cSCC patients treated in Cohorts 1, 2, and 3, 4 had a pathologic complete response (100% tumor clearance) at Day 36.
• One patient had a near complete response (>90% clearance) and 1 patient had a partial response (>50% clearance).
• The other 3 cSCC and one metastatic melanoma patient had a pathologic non-response (< 50% clearance).
• No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed.
• The fourth cohort is currently enrolling and treating patients, with completion of enrollment expected in the third quarter of 2025.
• In December 2024 and January 2025, Phio raised approximately $9.2 million in registered direct offerings and concurrent private placements.
• An additional $2.9 million was raised from the exercise of warrants previously issued on July 12, 2024.
• The company believes it has sufficient capital to complete the treatment phase of the Phase 1b trial.
• Research and development expenses decreased by 23% to $0.886 million for the three months ended March 31, 2025.
• General and administrative expenses decreased by 7% to $0.986 million for the same period.
• Net loss was $1.8 million for the three months ended March 31, 2025, compared to $2.2 million for the same period in 2024.
• Cash and cash equivalents were approximately $13.3 million at March 31, 2025, compared to $5.4 million at December 31, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to promising clinical trial results and a strengthened financial position, although the company is still loss making.

Positives

• Positive clinical trial results for PH-762 in cSCC patients, with a high rate of complete responses.
• Successful capital raising efforts, securing sufficient funding to complete the Phase 1b trial.
• Decrease in research and development expenses, indicating improved cost management.
• Strong cash position, providing financial stability for ongoing operations and clinical development.

Negatives

• The other 3 cSCC and one metastatic melanoma patient had a pathologic non-response (< 50% clearance).
• The company reported a net loss of $1.8 million for the three months ended March 31, 2025, although this is an improvement compared to the previous year.

Risks

• The success of clinical trials is not guaranteed, and future results may not replicate the positive outcomes observed in the Phase 1b trial.
• The company's reliance on its INTASYL technology platform poses a risk if the technology proves to be less effective than anticipated.
• The company needs to secure additional funding beyond the current Phase 1b trial, which could be challenging in the future.
• The biopharmaceutical industry is highly competitive, and Phio Pharmaceuticals faces competition from other companies developing cancer therapies.

Future Outlook

The company expects to complete enrollment in the Phase 1b trial in the third quarter of 2025 and believes it has sufficient capital to complete the treatment phase of the trial. The company also sees potential for RXI-231 in treating hyperpigmentation disorders.

Industry Context

Phio Pharmaceuticals is operating in the competitive immuno-oncology space, focusing on siRNA gene silencing technology. The positive clinical trial results for PH-762 could position the company favorably in the development of non-surgical treatments for skin cancers.

Comparison to Industry Standards

• The 100% tumor clearance rate in 4 out of 9 cSCC patients in Phio's Phase 1b trial is a promising result compared to standard treatments like surgery and radiation.
• Companies like Moderna and BioNTech are also exploring mRNA-based cancer therapies, but Phio's siRNA approach offers a different mechanism of action.
• The $13.3 million cash position provides Phio with a runway to advance its clinical programs, but it will need to secure additional funding to support long-term development and commercialization efforts.

Stakeholder Impact

• Shareholders may experience increased confidence due to the positive clinical trial results and improved financial position.
• Employees may benefit from the company's stability and growth prospects.
• Patients with skin cancer may have access to a potential non-surgical treatment option.
• The company's suppliers and partners may benefit from increased business opportunities.

Next Steps

• Complete enrollment in the fourth cohort of the Phase 1b clinical trial in the third quarter of 2025.
• Continue to analyze and present data from the Phase 1b clinical trial.
• Advance the development of RXI-231 for treating hyperpigmentation disorders.
• Explore potential collaborations and partnerships to further develop and commercialize its product candidates.

Key Dates

Keywords

Phio Pharmaceuticals, PH-762, INTASYL, siRNA, Clinical Trial, Cancer, cSCC, Melanoma, Financial Results, Biopharmaceutical